Subsequently, gossypol was advanced to clinical trials as a small‐molecule inhibitor of Bcl‐xL, Bcl‐2 and Mcl‐1.43 In 2004 Bradford and co‐workers reported that (−)‐gossypol was acting as a BH3 domain mimetic, making it a pan inhibitor of the Bcl‐2 family of proteins.44 Subsequently, (−)‐gossypol was shown to delay the onset of androgen‐independent prostate cancer in vivo,45 chemosensitise prostate cancer cells (PC‐3) to docetaxel both in vitro and in vivo, and was proven to increase the availability of the pro‐apoptotic proteins Puma and Noxa.46 The gene discussed is BCL2; the disease is prostate cancer.